Alector Reports 2020 First Quarter Financial Results and Business Highlights
May 13, 2020 08:00 ET
|
Alector, Inc.
Provides business continuity update regarding COVID-19Continued execution across immuno-neurology platformOn track to initiate pivotal Phase 3 trial of AL001 in patients with frontotemporal dementia...
Alector to Present at the Bank of America Securities Virtual Health Care Conference
May 07, 2020 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman,...
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
March 25, 2020 17:00 ET
|
Alector, Inc.
AL008 is Alector’s dual function SIRP-alpha inhibitor and Fc gamma receptor activator antibody targeting the innate immune system for oncology indicationsThe partnership with Innovent enables Alector...
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights
March 24, 2020 16:05 ET
|
Alector, Inc.
Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019 On track to initiate pivotal Phase 3 trial in patients with...
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
March 23, 2020 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is...
Alector to Present at the Cowen 40th Annual Health Care Conference
February 24, 2020 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal,...
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia
February 05, 2020 08:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food...
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 03, 2020 18:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its...
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering
January 31, 2020 08:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters...
Alector Announces Upsizing and Pricing of Public Offering
January 29, 2020 21:41 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an...